

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

**Kintara (NASDAQ/KTRA) – Neutral Rated**

October 31, 2023

**Kintara: VAL-083 Fails to Show Benefit vs. SOC in GBM**

Jason H. Kolbert

Managing Director & Senior Analyst  
jkolbert@dawsonjames.com

Kintara announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program. We have removed VAL-083 from our model. We have not yet included REM-001 in our model and anticipate doing so as we work to understand both the risk, proof of concept data and market opportunity for this cancer therapy.

**Investment Highlights**


**REM-001:** REM-001 is a second-generation photodynamic therapy (PDT) photosensitizer agent that has undergone late-stage clinical development in previous clinical trials showing a complete response in approximately 80% of evaluable tumor sites. REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second-generation photosensitizer drug that has undergone late-stage clinical development, and which we believe possesses multiple advantages over earlier-generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy-to-use fiber optic wand that the physician employs to directly illuminate the tumor with light.

REM-001 has been granted orphan drug designations for the treatment of recurrent basal cell carcinoma nevus syndrome (BCCNS) and ovarian cancer. In addition, the FDA has granted a fast-track designation for REM-001 in CMBC.

**Almost a year ago Kintara stated:** REM-001 was studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is focused on securing the funding necessary to restart a 15-patient study in CMBC patients in advance of a Phase 3 study.

**Valuation.** We have removed VAL-083 from our model. We have not yet added our model REM-001. As a result, we are neutral rated as we work to access the risk and market opportunity for REM-001

**Risk Factors:** Investment Risk, Market Share Risk, Regulatory Risk, Commercial Risk, and Financial Risk.



Source: Kintara

Stock Data			
52-Week Range	\$2.70	-	\$15.50
Shares Outstanding (mil.)	1.7		
Market Capitalization (mil.)	\$7		
Enterprise Value (mil.)	-\$1		
Debt to Capital	0%		
Book Value/Share	\$5.28		
Price/Book	1		
Average Three Months Trading Volume (K)	20		
Insider Ownership	2.7%		
Institutional Ownership	1.7%		
Short interest (mil.)	2.1%		
Dividend / Yield	\$0.00/0.0%		




**Exhibit 1. Income Statement**

Kintara Pharmaceuticals Inc. (KTRA): Income Statement ('000)	6. 2018 YE	6. 2019 A	6. 2020 A	6. 2021 YE	6. 2022 YE	1Q23A	2Q23A	3Q23A	4Q23A	6. 2023 YE	6. 2024 YE	6. 2025 YE	6. 2026 YE	6. 2027 YE	6. 2028 YE	6. 2029 YE	6. 2030 YE
FYE-Jun 30	6.2018	6.2019 A	6.2020A	6.2021	6.2022	3Q22A	4Q22A	1Q23A	2Q23A	6.2023	6.2024	6.2025	6.2026	6.2027	6.2028	6.2029	6.2030
<b>Revenue (\$000)</b>																	
REM-001					0					0	0	0	0	0	0	0	0
VAL-083 U.S.										0							
VAL-083 ROW																	
License Fees and Royalties (China sales)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Revenue</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Expenses</b>																	
Cost of Goods Sold	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
COGS % of revenue				10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
Sales, General and administrative expenses	4,042	4,736	4,515	8,467	7,509	1,475	1,440	1,297	1,273	5,485	10,000	10,100	10,201	10,303	10,406	10,510	10,615
SG&A % of revenue																	
Research and Development	7,133	3,662	4,684	12,895	15,173	3,171	2,059	2,005	2,076	9,311	12,000	12,120	12,241	12,364	12,487	12,612	12,738
R&D % of revenue																	
Non-GAAP, Adj				16594													
<b>Total expenses</b>	<b>11,175</b>	<b>8,398</b>	<b>9,198</b>	<b>37,956</b>	<b>22,682</b>	<b>4,646</b>	<b>3,499</b>	<b>3,302</b>	<b>3,349</b>	<b>14,796</b>	<b>16,766</b>	<b>19,562</b>	<b>19,758</b>	<b>19,955</b>	<b>20,155</b>	<b>20,357</b>	<b>20,560</b>
Oper. Inc. (Loss)	(11,175)	(8,398)	(9,198)	(37,956)	(22,682)	(4,646)	(3,499)	(3,302)	(3,349)	(14,796)	(16,766)	(19,562)	(19,758)	(19,955)	(20,155)	(20,357)	(20,560)
Change in fair value of derivative liability	60	(434)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability due to change in warrant terms		126															
Issuance of shares to Valent																	
Loss on exchange of warrants																	
Foreign exchange gain	(57)	18	3	5	7	11	45	(1)	5	60	-	-	-	-	-	-	-
Interest expense			(75)	50	14	39		38	10	87	-	-	-	-	-	-	-
Interest income	33	(61)	-	16	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total non-operating income</b>	<b>36</b>	<b>(350)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Pretax Income</b>	<b>(11,138)</b>	<b>(8,048)</b>	<b>(9,126)</b>	<b>(38,012)</b>	<b>(22,661)</b>	<b>(4,596)</b>	<b>(3,454)</b>	<b>(3,265)</b>	<b>(3,334)</b>	<b>(14,649)</b>	<b>(16,766)</b>	<b>(19,562)</b>	<b>(19,758)</b>	<b>(19,955)</b>	<b>(20,155)</b>	<b>(20,357)</b>	<b>(20,560)</b>
Income Tax Benefit (Provision)					(2,740)							(3,521)	(4,347)	(4,590)	(4,837)	(5,089)	(7,196)
<b>Tax Rate</b>					<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>18%</b>	<b>22%</b>	<b>23%</b>	<b>24%</b>	<b>25%</b>	<b>35%</b>
<b>GAAP Net Income (loss)</b>	<b>(11,281)</b>	<b>(8,048)</b>	<b>(9,126)</b>	<b>(38,012)</b>	<b>(24,857)</b>	<b>(4,596)</b>	<b>(3,454)</b>	<b>(3,265)</b>	<b>(3,334)</b>	<b>(14,649)</b>	<b>(16,766)</b>	<b>(16,041)</b>	<b>(15,411)</b>	<b>(15,366)</b>	<b>(15,318)</b>	<b>(15,267)</b>	<b>(13,364)</b>
Preferred stock dividend	176.24	80.43	8.62	730	(8.00)	364	2.00	2.00	2.00	370							
<b>Net and comprehensive loss available to common stockholders</b>	<b>(11,315)</b>	<b>(9,178)</b>	<b>(9,135)</b>	<b>(38,012)</b>	<b>(25,131)</b>	<b>(4,960)</b>	<b>(3,456)</b>	<b>(3,266)</b>	<b>(3,334)</b>	<b>(15,019)</b>	<b>(16,766)</b>	<b>(16,041)</b>	<b>(15,411)</b>	<b>(15,366)</b>	<b>(15,318)</b>	<b>(15,267)</b>	<b>(13,364)</b>
<b>GAAP-EPS</b>	<b>(0.55)</b>	<b>(1.28)</b>	<b>(0.87)</b>	<b>(1.85)</b>	<b>(0.52)</b>	<b>(0.06)</b>	<b>(2.10)</b>	<b>(1.94)</b>	<b>(0.15)</b>	<b>(9.27)</b>	<b>(0.46)</b>	<b>(0.38)</b>	<b>(0.37)</b>	<b>(0.36)</b>	<b>(0.36)</b>	<b>(0.36)</b>	<b>(0.31)</b>
Non GAAP EPS (dil)	(0.55)	(0.87)	(0.87)	(1.85)	(0.47)	(0.06)	(2.10)	(1.94)	(0.15)	(9.27)	(0.45)	(0.36)	(0.34)	(0.32)	(0.31)	(0.30)	(0.25)
Wgtd Avg Shrs (Bas) - '000s	20,861	2,575	10,444	32,297	48,702	73,205	1,643	1,681	21,683	1,620	36,752	41,914	42,082	42,251	42,420	42,590	42,760
Wgtd Avg Shrs (Dil) - '000s	20,861	2,575	10,444	32,297	63,799	73,205	1,643	1,681	21,698	1,620	37,396	44,066	45,855	47,717	49,655	51,671	53,769

Source: Dawson James

**Important Disclosures:**

**Price Chart:**



**Price target and ratings changes over the past three years:**

- Update – January 11, 2021 – Buy \$4.00
- Update – January 21, 2021 – Buy \$4.00
- Update – February 1, 2021 – Buy \$4.00
- Update – February 25, 2021 – Buy \$5.00
- Update – April 14, 2021 – Buy \$5.00
- Update – May 18, 2021 – Buy \$5.00
- Update – May 26, 2021 – Buy \$5.00
- Update – July 1, 2021 – Buy \$5.00
- Update – August 17, 2021 – Buy \$5.00
- Update – September 22, 2021 – Buy \$5.00
- Update – December 2, 2021 – Buy \$5.00
- Update – January 19, 2022 – Buy \$5.00
- Update – February 14, 2022 – Buy \$5.00
- Update – March 18, 2022 – Buy \$5.00
- Price Target Change – April 12, 2022 – Buy \$3.00
- Rating Change – Buy to Neutral May 16, 2022 – NA
- Update – Neutral September 8, 2022 – NA
- Update – Neutral September 26, 2022 – NA
- Update – Neutral September 29, 2022 – NA
- Update – Neutral October 19, 2022 – NA
- Update – Neutral November 10, 2022 – NA
- Update – Neutral November 18, 2022 – NA
- Update – Neutral December 15, 2022 – NA
- Update – Neutral February 21, 2023 – NA
- Update – Neutral May 2, 2023 – NA
- Update – Neutral May 11, 2023 – NA
- Update – Neutral June 30, 2023 – NA
- Update – Neutral September 19, 2023 – NA
- Update – Neutral September 26, 2023 – NA
- Update – Neutral October 31, 2023 – NA

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject Company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not

received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company(s). The Firm has received other compensation from the subject Company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company(s) in this report and may increase or decrease holdings in the future. As of September 27, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 27-Sep-23

	Company Coverage		Investment Banking	
<b>Ratings Distribution</b>	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	22	64.70%	3	8.80%
Market Perform (Neutral)	12	35.30%	3	8.80%
Market Underperform (Sell)	0	0%	0	0.00%
<b>Total</b>	<b>34</b>	<b>100%</b>	<b>6</b>	<b>17.60%</b>

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.